国: オーストラリア
言語: 英語
ソース: Department of Health (Therapeutic Goods Administration)
paclitaxel, Quantity: 100 mg
Cipla Australia Pty Ltd
Injection, powder for
Excipient Ingredients: Albumin; N-acetyl-dl-tryptophan; sodium octanoate
Intravenous
1 x 50 mL vial
(S4) Prescription Only Medicine
Metastatic breast cancer: Cipla Paclitaxel is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. Non-small Cell Lung Cancer: Cipla Paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. Metastatic Adenocarcinoma of the Pancreas: Cipla Paclitaxel, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.
Visual Identification: Nano-paclitaxel injection is a sterile white to yellow lyophilized cake or powder in a 50 mL USP Type I flint glass vial.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius
Registered
2020-10-29